866-997-4948(US-Canada Toll Free)

Non Malignant pain Global Clinical Trials Review, H2, 2015

Published By :

GlobalData

Published Date : Dec 2015

Category :

Pharmaceutical

No. of Pages : 68 Pages

Non Malignant pain Global Clinical Trials Review, H2, 2015

Summary

GlobalData's clinical trial report, Non Malignant pain Global Clinical Trials Review, H2, 2015" provides an overview of Non Malignant pain clinical trials scenario. This report provides top line data relating to the clinical trials on Non Malignant pain. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDatas proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Non Malignant pain to Central Nervous System Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Non Malignant pain to Central Nervous System Clinical Trials 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Non Malignant pain Therapeutics Clinical Trials 27
Prominent Drugs 29
Clinical Trial Profile Snapshots 30
Appendix 65
Abbreviations 65
Definitions 65
Research Methodology 66
Secondary Research 66
About GlobalData 67
Contact Us 67
Disclaimer 67
Source 68

List of Tables
Non Malignant pain Therapeutics, Global, Clinical Trials by Region, 2015* 6
Non Malignant pain Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Non Malignant pain Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Non Malignant pain Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015* 10
Non Malignant pain Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11
Non Malignant pain Therapeutics Clinical Trials, North America, Top Countries, 2015* 12
Non Malignant pain Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* 13
Non Malignant pain Therapeutics Clinical Trials, Central and South America, Top Countries, 2015* 14
Proportion of Non Malignant pain to Central Nervous System Clinical Trials, G7 Countries (%), 2015* 15
Non Malignant pain Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16
Non Malignant pain Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17
Proportion of Non Malignant pain to Central Nervous System Clinical Trials, E7 Countries (%), 2015* 18
Non Malignant pain Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 19
Non Malignant pain Therapeutics, Global, Clinical Trials by Phase, 2015* 20
Non Malignant pain Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 21
Non Malignant pain Therapeutics, Global, Clinical Trials by Trial Status, 2015* 22
Non Malignant pain Therapeutics Clinical Trials, Global, by End Point Status, 2015* 23
Non Malignant pain Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 24
Non Malignant pain Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 25
Non Malignant pain Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 26
Non Malignant pain Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 28
Non Malignant pain Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 29

List of Figures
Non Malignant pain Therapeutics, Global, Clinical Trials by Region (%), 2015* 6
Non Malignant pain Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 7
Non Malignant pain Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Non Malignant pain Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015* 10
Non Malignant pain Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11
Non Malignant pain Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12
Non Malignant pain Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2015* 13
Non Malignant pain Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2015* 14
Proportion of Non Malignant pain to Central Nervous System Clinical Trials, G7 Countries (%), 2015* 15
Non Malignant pain Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16
Non Malignant pain Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17
Proportion of Non Malignant pain to Central Nervous System Clinical Trials, E7 Countries (%), 2015* 18
Non Malignant pain Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 19
Non Malignant pain Therapeutics, Global, Clinical Trials by Phase (%), 2015* 20
Non Malignant pain Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 21
Non Malignant pain Therapeutics, Global, Clinical Trials by Trial Status, 2015* 22
Non Malignant pain Therapeutics Clinical Trials, Global, by End Point Status, 2015* 23
Non Malignant pain Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 24
Non Malignant pain Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 25
Non Malignant pain Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 26
Non Malignant pain Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 27
Non Malignant pain Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 29
GlobalData Methodology 66

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *

Upcoming Reports

  • Drug Discovery Technologies Market - Global Industry Analysis, Share, Size, Growth, Trends, And Forecast, 2012 - 2018

    Drug discovery technologies play a significant role in the field of pharmaceuticals as they heavily contribute to the introduction of drugs to the market. The application of drug discovery technologies have a significant opportunity in  the launch of drugs for severe diseases such as cancer, cardiovascular diseases, Parkinson’s disease, central nervous system disorders and others. However, the slow growth in the introduction of block...

  • Ureter Cancer Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

    Ureter cancer or renal pelvis cancer represents a cancer type affecting the kidney’s pelvis (tube passing the urine from kidney to the bladder). These cancers account for around five percent of all the cancer types related to upper urinary tract and kidney. The occurrence of ureter cancer is more common in men (aged more than 65 years) than women. Ureter or renal pelvis cancer tumors are usually transitional cell cancers and around ten pe...

  • Angina Pectoris Market - Global Industry Size, Market Share, Trends, Analysis And Forecasts 2012 - 2018

    Angina pectoris market is expected to grow at the CAGR of 3.5% and reach the value of $12,707.4 million by the year 2018. This growth is primarily driven by the increase in number of patients undergoing treatment for angina pectoris and likely approval of new therapies like varespladib and Generx that are in late stage of clinical development. If approved, these products are expected to contribute in the growth of angina pectoris industry...